Compare Medtronic PLC (MDT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Recursion Pharmaceuticals Inc — how do they compare? Medtronic PLC trades at $82.79 (market cap $106.61B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Medtronic PLC is far larger — about 69.7× Recursion Pharmaceuticals Inc's market cap, and Medtronic PLC pays a 3.46% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MDT | RXRX | |
|---|---|---|
Market Cap | $106.61B | $1.53B |
Sector | Health | Health |
52-Week High | $105.35 | $6.79 |
52-Week Low | $73.75 | $2.84 |
Enterprise Value | $125.36B | $946.50M |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
